HOME >> BIOLOGY >> NEWS
License to kill: development of killer T cells observable

New model could show how immune system is thwarted by HIV and cancer

BOSTON-November 22, 1999-Researchers at the Center for Blood Research and Harvard Medical School report in the November 23 Proceedings of the National Academy of Sciences the development of an animal model that literally illuminates one of the most dramatic and, until now, obscure events in the body: how the immune system turns immature T cells into specialized killer, or cytotoxic, T cells, capable of seeking out and destroying cells maimed by cancer and infection.

"Now, we have a model that makes it possible to look at a unique and important subset of cells; first to identify it and then analyze it in novel ways," says Ulrich von Andrian, MD, PhD, HMS associate professor of pathology. "This system might allow us to get a better understanding of what provides the T cells' license to kill," he says. Ultimately, the model could be used to clarify such diseases as cancer and AIDS. Some researchers have suspected that viruses and tumor cells may thwart the immune system by taking away T cells' license to kill-that is, by sabotaging the cellular machinery that enables them to attack unwanted cells.

"During the initial stages of an HIV infection, there are lots of cytotoxic T cells in the body but, for some reason, they are not able to contain the infection," says N. Manjunath, PhD, research fellow, and lead author of the study. "Is there a defect in these cells? Understanding normal differentiation with our new model, we might help answer this question."

One of the biggest obstacles to understanding this crucial transformation has been spotting members of this elite corps in large enough numbers to study them. Relatively rare-white blood cells in general number about one in one thousand cells in the bloodstream-T cells also move with the same velocity as other cells in the blood so they tend to get lost in the crush.

To flush them out, von Andrian, Manjunath,
'"/>

Contact: John Lacey
john_lacey@hms.harvard.edu
617-432-0441
Harvard Medical School
22-Nov-1999


Page: 1 2

Related biology news :

1. "Protect Wild Dolphins" License Plate Sales To Fund Wild Dolphin Research Efforts Throughout Florida
2. Washington University Licenses Its New Antibacterial Technology
3. Maillinckrodt Medical Licenses Invention For Concentration Of Rhenium Radioisotopes
4. Supelco Licenses ORNL Solid Sorbent Air Sampling Material
5. Bronfenbrenner book sums up human development
6. OutFoxed! New research may redefine late-stage cardiac development
7. Disease diagnosis, drug development focus of UH profs biochip research
8. Jefferson Lab detector technology aids development of cystic fibrosis therapy
9. Joslin Diabetes Center launches research section on developmental and stem cell biology
10. LBP-1a gene mutation linked to disruption of normal fetal development
11. Method to visualize gene activity may provide insight into normal development & genome function

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: License kill development killer cells observable

(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2
(Date:5/23/2013)... , May 23, 2013 VG Energy, ... alliance with DAK Renewable Research to conduct field ... yield. VG Energy is a majority owned subsidiary ... VG Energy,s exclusively licensed compound LipidMax ... oil yield in plants, possessing a wide variety ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 ... made trips to supermarkets to search for the ... grocery store aisles. Results from a year long study ... bacteria level in foods, specifically meats, over previous years. ... explains how the growth of antibiotic resistant bacteria in ...
(Date:5/23/2013)... BETHESDA, Md. , May 23, 2013 ... a biotechnology company developing DCVax ® personalized immune ... will use its exhibit at this year,s American Society ... to highlight its leadership role in immune ... The ASCO annual meeting is the pre-eminent conference ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
Cached News: